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Abstract 
Background: A subset of individuals with obesity display a normal cardiometabolic profile, 
termed metabolically healthy obesity (MHO). 
Objectives: To examine the prevalence and predictors of MHO in adolescents.  
Methods: Participants included 316 males and 316 females aged 12-19-years with a BMI ≥95th 
percentile from the 1999-2010 National Health and Nutrition Examination Surveys.  First, MHO 
was defined as being free of type 2 diabetes, hypertension, and dyslipidemia and having <2 
metabolic syndrome criteria.  Second, MHO was defined as being free of all metabolic syndrome 
criteria, insulin resistance, and inflammation.  
Results: The prevalence of MHO varied from 7-74% depending on the definition.  Lower 
obesity and lower insulin-resistance predicted MHO in males and females (p<0.01).  
Associations between dietary components and MHO were weak and inconsistent.  Physical 
activity and inflammation were not associated with MHO (p>0.05). 
Conclusions: An emphasis on managing weight and insulin-resistance responses should be a 
central goal for adolescents with obesity. 
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Chapter One: General Introduction 
Adolescent obesity is associated poor dietary habits, insufficient physical activity and 
cardiometabolic health aberrations including hypertension, hyperglycemia and dyslipidemia1.  
Approximately 80% of obese adolescents become obese adults2, and these obesity-related 
cardiometabolic health aberrations also track into adulthood3 and increase the risk of incident 
type 2 diabetes, cardiovascular disease (CVD) and the risk of mortality1.  However, despite the 
documented health risks associated with obesity, adolescent obesity is a heterogeneous condition 
wherein a subset does not present with these cardiometabolic risk factors4, termed metabolically 
healthy obesity (MHO).  There is a large discrepancy in the reported prevalence of MHO due to 
variations in the criteria used to define MHO, however a consistently lower prevalence is 
observed in males than females4,5. 
Some evidence suggests that adolescents with MHO may become healthy, non-obese 
adults or remain MHO as adults6.  As most attempts to treat obesity have proven to have limited 
success7, it may therefore be a more attainable goal for adolescents with obesity to achieve or 
maintain MHO as an early intervention.  The determinants of MHO have been debated, but it has 
been suggested that differences in cardiometabolic function between adolescents with MHO and 
their peers, with metabolically unhealthy obesity (MUO) may be related to differences in diet or 
physical activity habits8, or variability in the level of obesity8, obesity-related sub-clinical 
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inflammation9 or insulin-resistance responses9.    As diet and physical activity habits also tend to 
track into adulthood10, diet and physical activity may be important modifiable factors for 
maintaining metabolic health in obesity.  
To our knowledge, no study to date has used a large nationally representative sample to 
determine which of these factors is most important in predicting MHO in adolescents.  The 
objective of this study was to investigate the prevalence of adolescents with MHO and the 
independent relationships between obesity, diet, physical activity, insulin-resistance and 
inflammation with MHO in male and female adolescents. 
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Chapter Two: Review of the Literature 
Introduction 
The prevalence of obesity in adolescents has tripled in the past three decades, reaching 
21% in American adolescents11 and 10% in Canadian adolescents12.  Obesity is associated with 
an array of health conditions including but not limited to type II diabetes, cardiovascular disease, 
certain types of cancer, gout, osteoarthritis, reproductive disorders, depression, chronic 
obstructive pulmonary disease, non-alcoholic fatty liver disease, and back pain13.  These obesity-
related health conditions pose a large burden on the health care system, costing Canada 
approximately 11 billion13 and the US approximately 13 billion14 dollars annually in health care 
services.  While most of these obesity-related health conditions do not become apparent until 
adulthood, certain comorbidities associated with obesity once thought to only be applicable to 
adults, are now increasing at an alarming rate in adolescents15.  For instance, most adolescents 
with obesity have at least one additional risk factor for type II diabetes and CVD16, such as 
hypertension, dyslipidemia, hyperglycemia, insulin-resistance and inflammation, which are 
termed cardiometabolic risk factors1.  Unfortunately, these metabolic aberrations tend to track 
into adulthood3, and prolonged exposure may result in irreversible damage1.   
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Metabolic Health 
The metabolic syndrome is a condition characterized by the clustering of at least three of 
the following cardiometabolic risk factors: elevated waist circumference (WC), blood pressure 
(BP), glucose, triglycerides and low high-density lipoprotein cholesterol (HDL-C)1.  Early and 
continued development of these cardiometabolic risk factors, clustered or in isolation, has been 
demonstrated to increase and accelerate the risk for developing type II diabetes and CVD later in 
life1.  With the increasing prevalence of the metabolic syndrome in youth15, it has been proposed 
for first time in modern history, that youth may have a shorter life expectancy than their 
parents15. 
Although obesity is associated with an increased risk of developing health complications, 
variability exists in the quantity and severity of comorbidities experienced by individuals with 
obesity17.  Some individuals with obesity are free of comorbidities, while others display an array 
of health complications17.  Consequently, numerous classification systems have been developed 
to diagnose the clustering and/or severity of health risks associated with obesity.  For instance, a 
recently proposed obesity classification system, known as the Edmonton Obesity Staging System 
(EOSS)18, classifies adults with obesity according to a 5-point ordinal scale based on 
psychological, cardiometabolic, and functional status18.  On the lower end of the scale, the EOSS 
stage 0 represents adults with obesity that are free of obesity-related health complications and, on 
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the other end of the scale, stage 4 represents end-stage conditions requiring palliative care18.  
Other methods of classifying the health risks associated with obesity include the classification of 
adults with obesity according to the presence of the metabolic syndrome17, metabolic syndrome 
criteria17, and/or other cardiometabolic risk factors such as inflammation19, insulin-resistance19, 
elevated low density lipoprotein cholesterol (LDL-C)20, and/or elevated total cholesterol20.  
These classification systems often differentiate individuals with obesity having limited 
comorbidities, termed metabolically healthy obesity (MHO), from individuals displaying an 
array of cardiometabolic health conditions, termed metabolically unhealthy obesity (MUO).   
Although fewer classification systems have been proposed to diagnose the health risks 
associated with obesity in adolescents, most differentiate MHO from MUO in adolescence using 
markers of insulin-sensitivity or metabolic syndrome criteria.  Most commonly, insulin-
sensitivity is assessed using the homeostatic model assessment of insulin-resistance (HOMA-
IR)8,9, whereas studies classifying adolescents using the absence of the metabolic syndrome often 
use a variety of criteria, such as pediatric IDF criteria4,21, modified NCEP III criteria22 or age-
specific criteria5 for the metabolic syndrome, or combinations of these approaches to define 
MHO.  Most MHO definitions have unique cut-points for the levels of BP, glucose, triglycerides, 
and HDL-C or HOMA-IR considered as elevated as metabolic syndrome criteria cut-offs 
themselves and what the presence of metabolic syndrome in adolescences means are debated.  
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These differences in defining ‘metabolically healthy’ make it difficult to compare adolescents 
with MHO from one study to another.  These discrepancies may account for some of the 
variance in the reported prevalence of MHO, which ranges from 16-68%4,5,8,9,21,22.   
Although most report that more than half of adolescents with obesity have MHO4,9,21,22, 
adolescents with isolated type 2 diabetes, dyslipidemia or hypertension are often not excluded 
from the group with MHO unless these adolescents experience clustering of these conditions 
with other cardiometabolic risk factors.  However, it is questionable whether an individual with 
isolated type 2 diabetes can in fact be called ‘metabolically healthy’.  Therefore, in the present 
study we will investigate the prevalence and predictors of MHO using both a traditional and a 
more conservative definition as well as differences between these two definitions. 
Etiology 
The etiology of cardiometabolic aberrations in individuals with MUO is multifactorial, 
however, three main culprits may be responsible for this cardiometabolic dysfunction: obesity, 
insulin-resistance, and low-grade inflammation1.  Lifestyle factors such as diet and physical 
activity have also been demonstrated to influence obesity, insulin-resistance, low-grade 
inflammation, and MUO8,23.  The following section will provide a brief overview of the 
pathogenesis relating obesity, insulin resistance, low-grade inflammation, diet, and physical 
activity to the development of MUO.   
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Obesity 
Adipose tissue is a specialized tissue that stores energy in the form of triacylglycerols and 
also acts as an endocrine and paracrine organ releasing adipokines that may participate in the 
pathogenesis of obesity related comorbidities1.  During a period of positive energy balance, 
adipocytes expand, becoming larger in size (hypertrophy) and can trigger the generation of new 
adipocytes (adipogenesis) to increase the storage capacity for the excess triacylglycerol24.  
However, in some individuals, adipogenesis is impaired and is unable to match the need, and 
thus storage of triacylglycerols is achieved through hypertrophy in larger adipocytes, or in 
deposition of lipids in nonadipose tissues (ectopic fat), resulting in lipotoxicity25.  The size of the 
adipocytes is positively associated with the quantity of adipokines released, thus, individuals 
with obesity with larger adipocytes have greater adipokine secretion than individuals with a 
normal weight or obesity with smaller adipocytes26.  Adipocyte hypertrophy and adipokine 
hyper-secretion often lead to endoplasmic recticulum stress, apoptosis, macrophage infiltration, 
chronic low-grade inflammation, insulin resistance and the release of triglyceride-derived free 
fatty acids, all of which are related to MUO25.  Consequently, the severity of obesity, which is 
associated with the size of adipocytes, is positively associated with cardiometabolic dysfunction1 
and inversely associated with MHO8. 
Not only is the severity of obesity associated with MUO, but also the distribution of 
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adipose tissue24.  Two main types of adipose tissue exist: subcutaneous adipose tissue and 
visceral adipose tissue.  Subcutaneous adipose tissue comprises the adipose tissue depots found 
between the skin and the aponeuroses and fasciae of the muscles24 and visceral adipose tissue 
comprises the adipose depots found in the intrathoracic and intra-abdominopelvic regions, 
including ectopic fat in the liver, pancreas, etc24.  It has been hypothesized that excess visceral 
adiposity may be caused by the inability of subcutaneous adipose tissue to expand through 
adipogenesis during a period of positive energy balance27.  Differences are observed in the 
methods by which these adipose tissues are vascularized, innervated and to which blood flows to 
and from these areas24.  For instance, visceral adipose tissue is drained by the portal vein leading 
to the liver24.  Free fatty acids released from visceral adipose tissue thereby accumulate in the 
liver where they stimulate the production of very low-density lipoprotein triglycerides leading to 
insulin-resistance, dyslipidemia, and elevated blood pressure24.  The strongest correlate of 
visceral fat is waist circumference, and thus abdominal obesity is consistently associated with a 
lower likelihood of MHO than general obesity in adults19 and youth8. 
Insulin Resistance and Low-grade Inflammation 
Insulin resistance and low-grade inflammation are also commonly proposed culprits of 
cardiometabolic dysfunction that appear to be inter-related1.  Insulin resistance is a 
pathophysiological condition characterized by the inability of normal insulin concentrations to 
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produce a normal insulin response in peripheral tissues such as the muscle, liver, pancreas and 
adipose tissues26.  Pancreatic beta cells must therefore increase the secretion of insulin 
(hyperinsulinemia) to overcome hyperglycemia26.   Insulin resistance results in increased 
circulation of free fatty acids and hyperglycemia, and is thought to be the central metabolic 
abnormality in CVD and type 2 diabetes26.   
Chronic low-grade inflammation is characterized by the accumulation of lymphocytes, 
macrophages and plasma cells in tissues28.  Low-grade inflammation induces the cardiometabolic 
aberrations observed in individuals with MUO via several mechanisms.  Inflammatory cytokines 
induce adipocyte apoptosis and increase insulin resistance by inhibiting the insulin receptor 
substrate 1 signaling pathway26.  Inflammatory cytokines can also suppress lipoprotein lipase 
activity and increase hepatic synthesis of free fatty acids, resulting in dyslipidemia29.  
Inflammatory cytokines thus mediate several inter-related alterations in cardiometabolic 
pathways including free fatty acid metabolism, insulin sensitivity, oxidative stress, and the 
metabolic aberrations observed in MUO1.  Therefore, both HOMA-IR and C-reactive protein 
(CRP), commonly used measures of insulin resistance and inflammation, respectively, have been 
demonstrated to be inversely associated with MHO in adolescents with obesity21.  However, 
which of these factors is most central to metabolic function is still unclear.   
It is important to note that not all individuals with obesity experience insulin resistance 
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and/or low-grade inflammation and some individuals with a normal weight experience these 
cardiometabolic aberrations1.  Evidence exists to suggest that alternative factors including but 
not limited to dietary factors8,23, smoking28, gut microbiota28, or inadequate physical activity23,30 
may be the causal factors driving the insulin resistance and/or low-grade inflammation, and 
subsequently resulting in the obesity of the individual as well as the cardiometabolic aberrations 
observed in individuals with MUO31.  For example, studies in both mice and rats have 
demonstrated that inflammation may result from these alternative factors before the appearance 
of obesity and disabling these inflammatory pathways has prevented the development of obesity 
under similar obesity-inducing conditions31.  Similarly, longitudinal studies in humans have 
demonstrated that accelerated weight gain is preceded by changes in inflammatory cytokines29.  
However, temporal and causal relationships of obesity, insulin resistance and inflammation with 
MUO remain unclear29.   
As the hypotheses suggesting that obesity, insulin-resistance or low-grade inflammation 
result in the metabolic derangements of MUO are not mutually exclusive, all three are suggested 
to play a role in the pathogenesis of cardiometabolic risk factor clustering1.  Therefore, it has 
been proposed that the differences in metabolic function between the MUO and MHO 
phenotypes may be related to the individual variability in obesity, inflammation, and/or insulin-
resistance21.  
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Diet 
Energy restriction, as well as several alterations in macronutrient composition have been 
demonstrated to improve body composition and overall cardiometabolic health32.  Even without 
caloric restriction, decreasing dietary carbohydrate intake, or replacing high glycemic index 
carbohydrates with fiber-dense carbohydrates, has been suggested to decrease plasma 
triglycerides, increase HDL-C, reduce plasma glucose concentrations, and lower BP32,33.  
Similarly, decreasing total fat intake, especially saturated fat intake and cholesterol are 
alternative methods of improving cardiometabolic health33.  Further, replacing saturated fat with 
polyunsaturated and monounsaturated fats have been demonstrated to improve components of 
cardiometabolic health, particularly insulin resistance and inflammation32.  Therefore, 
maintaining a balance between carbohydrate and fat consumption, while limiting saturated fat, 
simple carbohydrate, and cholesterol intake may help maintain or improve cardiometabolic 
health.  The current recommendations suggest limiting total fat intake to approximately 30% of 
daily caloric intake and saturated fat to 7-10% of daily caloric intake, while limiting cholesterol 
intake to 300mg per day34.  At least 14 g/1000 kcal should be derived from fiber and 
carbohydrates should comprise approximately 50-55% of daily caloric intake and proteins 
approximately 15-20% of daily caloric intake34.  
Studies also suggest that diet influences cardiometabolic health in youth35, however 
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research in youth is less abundant.  The few studies that have investigated these associations 
have suggested that lower fiber36, polyunsaturated fat intake37 and protein38 and higher 
carbohydrate39, saturated fat40, and total fat39 are associated with poorer cardiometabolic health.  
Further, only one study has investigated the association between dietary components specifically 
with MHO in adolescents and demonstrated that total fat intake is inversely associated with 
MHO, independent of waist circumference and physical activity8.  Since limited research is 
available on diet and MHO in the adolescent population, further studies are required to clarify 
these associations.  In the present study, we will examine the associations between total fat, 
saturated fat, polyunsaturated fat, monounsaturated fat, carbohydrates, protein, fiber and 
cholesterol with MHO in adolescents with obesity. 
Physical Activity 
Physical activity has been demonstrated to increase physical fitness, decrease adiposity 
and enhance overall cardiometabolic health41.  The greatest health benefits of physical activity 
are observed when transitioning from a state of inactivity to being active42.  Most of these health 
benefits can be acquired through moderate physical activity (MPA), although additional benefits 
are provided from vigorous physical activity (VPA)41.  The associations between physical 
activity and cardiometabolic health occur independent of obesity, however, they are weakened 
when researchers use self-reported measures of physical activity41.  
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The health benefits of physical activity are also observed in adolescents with obesity43, 
however, the association of physical activity specifically with MHO in adolescents with obesity 
has not yet been firmly established, as only two studies have investigated this association.  The 
first study used nationally-representative and self-reported data to examine MPA, VPA, 
moderate-vigorous physical activity (MVPA), muscle strengthening activities, active 
transportation, and physical activity as a function of metabolic equivalent of task (in minutes per 
week).  Despite the large number of analyses, none of the physical activity variables were 
significantly associated with MHO4.  Contrarily, data from a clinical pediatric weight 
management data, report a positive association between MVPA (in minutes per day) and MHO 
independent of obesity and diet, also using self-reported data8.  It is unclear why conflicting 
results were obtained from these studies, but due to the lack of studies examining this area, more 
research is needed.  The present study will further investigate the association between physical 
activity and MHO in attempt to add clarification to the limited and inconclusive literature.  As 
evidence exists to suggest that the association between physical activity and cardiometabolic 
health in youth is weaker in females41, the present study will investigate the association between 
physical activity and MHO in adolescents with obesity by sex.  
Summary of literature 
Unfortunately, few studies have investigated the prevalence and predictors of MHO in 
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adolescents with obesity in comparison to adult literature and most have included overweight 
adolescents in their analyses, portraying an inflated prevalence of MHO.  Furthermore, no study 
to date has examined the independent associations between obesity, diet, physical activity, and 
laboratory measures (insulin-resistance and inflammation) in relation to MHO using a nationally-
representative sample of adolescents with obesity.  Therefore the objectives of the present study 
are to investigate: 
 The prevalence of MHO in male and female adolescents with obesity using two 
definitions of MHO. 
 The association between obesity, diet, physical activity and laboratory measures with 
MHO in adolescents with obesity, by sex. 
 The independent associations between obesity, diet, physical activity and laboratory 
measures with MHO in adolescents with obesity, by sex. 
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Chapter Three: Methods 
Data Source and Sampling 
Data from the 1999-2010 years of the National Health and Nutrition Examination Survey 
(NHANES), an ongoing, cross-sectional study was analyzed. The NHANES is conducted by the 
National Center for Health Statistics for the Centers for Disease Control and Prevention and is 
composed of interview and physical examination components to assess the health and nutritional 
status of the U.S. population.  The NHANES uses a complex four-stage probability sampling 
method to obtain a nationally representative sample of the noninstitutionalized U.S. population.  
Informed consent was obtained from 18 and 19 year old participants, and parental consent and 
participant assent was obtained for participants under the age of 18 years.  All laws regarding 
human ethics were followed and the protocol was approved by the National Center for Health 
Statistics Ethics Review Board.  Details of the survey methods are described elsewhere44.   
Subjects 
The present study included NHANES participants ages 12 to 19 years with an age- and 
sex-specific BMI ≥95th percentile45 (n= 2370).  Participants who were (i) pregnant (n = 47), (ii) 
taking insulin (n=6), (iii) using tobacco or nicotine products within the past five days (n = 272), 
(iv) fasted for less than three hours46,47 (n = 438) and (v) having CRP concentrations greater than 
10mg/L48 (n = 1) were excluded.  Individuals with variable outliers, implausible values, or 
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missing values for either WC (n = 63), tobacco use within the past five days (n = 178), MPA (n = 
93), VPA (n = 81), energy intake (n = 84), total fat intake (n = 88), saturated fat intake (n = 90), 
monounsaturated fat intake (n = 83), polyunsaturated fat intake (n = 93), carbohydrate intake (n 
= 83), protein intake (n = 85), fiber intake (n = 86), cholesterol intake (n = 97), fasting 
triglycerides (n = 1383), fasting glucose (n = 1376), fasting insulin (n = 1385), fasting HDL-C (n 
= 228), CRP (n = 220), poverty income ratio (PIR; n = 180), systolic blood pressure (SBP; n = 
90) and diastolic blood pressure (DBP; n = 110) were also excluded from the analysis. The final 
sample included 316 male and 316 female adolescents with obesity. 
Demographic variables 
Information on age, gender, family size and income was obtained via home interviews.  
Demographic data were reported by a proxy for participants under the age of 16 years and were 
self-reported for participants aged 16 to 19 years.  Family size and income were used to compute 
PIR, a measure of socioeconomic status calculated as family income divided by the Department 
of Health and Human Services’ poverty guidelines based on family size, year and state49.  Values 
for PIR are provided on a continuous scale from “0” to “5”, with a value of "1" representing the 
poverty line. 
Anthropometric Measures 
WC was measured without clothing, to the nearest 0.1cm, at the midpoint between the 
17 
 
bottom of the rib and the top of the iliac crest during minimal respiration.  Weight was assessed 
to the nearest 0.1kg with a Toledo digital scale (Mettler-Toledo Inc, Columbus, OH) while 
participants wore underwear, disposable paper gowns and foam slippers.  Normal WC was 
defined as having a WC ≤ 90th percentile for age and sex50 or the adult cut-off, if lower51.  Height 
was measured to the nearest 0.1cm using a fixed stadiometer.  BMI percentiles were calculated 
from weight and height measurements using the Centers for Disease Control and Prevention age- 
and sex- specific growth charts45.  
Diet  
Data on diet was obtained using a 24-hr diet recall method.  Participants were asked to 
list the volume of all food and beverages consumed from midnight to midnight the day prior to 
arriving at the mobile examination center.  Measuring tools and food models were provided to 
aid participants with quantifying proportions.  Trained dietary interviewers recorded this 
information using the USDA automated pass method52.  During the years 2003-2010, the average 
of the two 24-hour diet recalls was used.  The dietary variables assessed in the present study 
include: energy intake (kcal), total fat (g), saturated fat (g), monounsaturated fat (g), 
polyunsaturated fat (g), carbohydrates (g), protein (g), fiber (g) and cholesterol (mg). Further 
details on NHANES diet-recall procedures can be found elsewhere53 
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Recreational Physical Activity 
Participants completed a questionnaire on physical activity, derived from the World 
Health Organization’s Global Physical Activity Questionnaire54, in the mobile examination 
center for 12-15 year old participants and in the participant’s homes for 16-19 year old 
participants.  Participants were asked to disclose information on frequency and duration (in 
minutes) of all recreational MPA and VPA they had engaged in for at least 10 minutes 
continuously, “in the past 30 days” for NHANES 1999-2006 and “in a typical week” for 
NHANES 2007-2010.  Recreational MVPA was calculated as the sum of recreational MPA and 
VPA in minutes per week.  Details on the NHANES physical activity questionnaire have been 
reported previously53. 
Laboratory Measures  
SBP and DBP are an average of two or three readings from a manual mercury 
sphygmomanometer in the mobile examination center following the protocol of the American 
Heart Association.  The use of hypertension medication was assessed via questionnaire.  Blood 
samples were drawn from the participants arm by a certified phlebotomist in the mobile 
examination center, processed, stored and shipped to various laboratories for analysis.  Fasting 
plasma glucose was measured using hexokinase methods.  Plasma insulin was measured using 
the radioimmunoassay double-antibody batch method in 1999-2002, the two-site 
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immunoenzymatic assay in 2003-2005, and the human insulin immunoassay method (ELISA) in 
2005-2010.  HOMA-IR55 was calculated as: fasting insulin (mU/L) x fasting plasma glucose 
(mmol/L)/ 22.5.  Blood CRP was quantified with a Behring Nephelometer.  Serum triglycerides 
were assessed enzymatically using a series of coupled reactions in 1999-2006, and a two-reagent 
end-point reaction in 2007-2010.  HDL-C levels were assessed using the Heparin-Mn 
precipitation method in 1999-2001 and the direct HDL method in 2003-2010.  Triglyceride and 
HDL-C levels were measured using a Hitachi 704 Analyzer in 1999-2004, Roche Hitachi 717 in 
2005, Roche Hitachi 717 and 912 in 2006, and a Roche Modular P chemistry analyzer in 2007-
2010.  Details of all NHANES laboratory protocol and procedures are available elsewhere53. 
Definition of MHO 
Two methods were used to define MHO.  The primary definition excluded adolescents 
with: (i) clinically diagnosable levels of fasting plasma triglyceride, glucose, HDL-C, and BP 
and (ii) two or more pre-clinical metabolic syndrome criteria (Table 1).  The secondary 
definition of MHO was more stringent as it excluded adolescents with: (i) any pre-clinical 
metabolic syndrome criteria (ii) insulin resistance or (iii) inflammation (Table 1).   
Statistical Analysis 
All statistical analyses were performed using SAS software version 9.3 (SAS Institute, 
Cary, NC) with a significance level of p<0.05.  Analyses were stratified by sex.  Due to the 
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complex sampling design of NHANES, sample weights were applied as recommended by the 
National Center for Health Statistics56.  Descriptive data are presented as means±standard errors 
and differences between MHO and MUO groups were determined using independent samples t-
tests.  In multivariable analyses, predictors were standardized using standard error to allow for 
comparisons between variables.  Logistic regressions adjusted for age and socioeconomic status 
were performed on the standard error of each independent variable using Proc Surveylogistic.  
Due to the high prevalence of MHO in the study sample, Odds Ratios and 95% Confidence 
Intervals (CI) were then transformed into Prevalent Risk (PR) and 95% CI.57.  The most 
significant predictor of MHO from each category (obesity, diet, physical activity, laboratory 
measure-primary MHO definition only) was then entered into a mutually-adjusted model with 
further adjustment for age and socioeconomic status. 
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Chapter Four: Results 
Participant Characteristics 
Figure 1A displays the proportion of adolescents with each cardiometabolic risk factor 
and Figure 1B displays the number of pre-clinical metabolic syndrome risk factors 
(triglycerides, glucose, HDL-C and BP) in the study sample.  The percentage of adolescents free 
of any of the four pre-clinical metabolic syndrome risk factors was 27% in males and 45% in 
females, and the proportion of adolescents with 0 or 1 pre-clinical metabolic syndrome risk 
factors was 55% in males and 79% in females (Figure 1B).  After excluding individuals with 
clinically diagnosable levels of metabolic syndrome risk factors, the prevalence of MHO was 
42% in males and 74% in females (Primary Definition).  Characteristics of the study sample by 
sex and metabolic health status are presented in Table 2.  Using the primary definition of MHO 
(<2 pre-clinical metabolic syndrome risk factors and no clinically diagnosable levels of 
metabolic syndrome risk factors), MHO males were younger, of a lower socioeconomic status, 
less obese, ate more total fat, saturated fat, monounsaturated fat, protein, fiber and cholesterol 
and were less insulin-resistant than MUO males.  MHO and MUO females did not differ in age, 
socioeconomic status, obesity, diet, or physical activity behaviours, however, they were less 
insulin-resistant than MUO females.  According to the secondary definition of MHO (no 
metabolic syndrome criteria, insulin-resistance and inflammation), the prevalence of MHO was 
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only 7% in males and 12% in females.  MHO males were of a higher socioeconomic status, less 
obese, reported a lower fiber intake, and participated in more MPA and VPA than MHO males.  
MHO females had a higher socioeconomic status, lower WC and participated in less VPA than 
MUO females.  
Predictors of MHO 
Using the primary definition of MHO, in males, BMI percentile, WC and carbohydrate 
intake were negatively associated with MHO and protein intake and cholesterol intake were 
positively associated with MHO (Table 3).  Physical activity did not predict MHO.  Lower 
insulin-resistance but not inflammation was associated with MHO.  In females, obesity was not 
associated with MHO and, of the dietary components, only a higher polyunsaturated fat intake 
predicted MHO.  Physical activity was not associated with MHO.  Lower insulin-resistance, but 
not inflammation was associated with MHO.  According to the secondary definition of MHO, in 
males, BMI percentile and WC were negatively associated with MHO (Table 3).  Unexpectedly, 
of the dietary components, only saturated fat intake was positively associated with MHO.  
Physical activity was not associated with MHO.  In females, lower WC and higher 
monounsaturated fat intake were associated with MHO.  Physical activity was not associated 
with MHO. 
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Independent Predictors of MHO 
To determine the independent associations between obesity, diet, physical activity, and 
laboratory measures with MHO, the most significant obesity, diet, physical activity and 
laboratory correlates (Definition 1 only) of MHO were entered into a mutually adjusted model 
with further adjustment for age and socioeconomic status (Table 4).  In males, the model for the 
primary definition of MHO included WC, carbohydrate intake, VPA and insulin-resistance, of 
which only WC and insulin-resistance remained significantly associated with MHO (Table 4).  
In females, the mutually adjusted model for the primary definition of MHO included WC, 
polyunsaturated fat, MVPA and insulin-resistance, of which higher polyunsaturated fat intake 
and lower insulin-resistance remained independently associated with MHO.  The model for the 
secondary definition of MHO in males included WC, saturated fat and MVPA, of which WC 
remained negatively associated with MHO.  The model predicting the secondary definition of 
MHO in females included WC, monounsaturated fat and VPA, of which only WC remained 
associated with MHO. 
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Chapter Five: Discussion 
The present study investigated the prevalence and predictors of MHO in a nationally 
representative sample of adolescents.  We demonstrated that only 7% of males and 12% of 
females with obesity could be classified as MHO using the most stringent definition, while 42% 
of males and 74% females were classified as MHO using a more commonly used definition.  
Lower WC and insulin-resistance were the most consistent predictors of MHO in both males and 
females.  No individual dietary component was consistently related to MHO and physical 
activity did not predict MHO.  Our data suggest that adolescents with obesity should strive to 
achieve or maintain lower WC and insulin-resistance. 
 Previous literature reporting the prevalence of MHO has used several definitions of the 
metabolic syndrome including the absence of insulin-resistance9 age-specific criteria5, pediatric 
IDF criteria4,21,5,58, modified NCEP III criteria22 or combinations of these approaches8,9 to define 
MHO.  Depending on the definition and the number of criteria used to define MHO, there can be 
large variations in the prevalence of MHO ranging from 16-68% in previous literature4,5,8,9,21,22,58 
and  7-79% in our study.  This variability emphasizes the need to harmonize the definition of 
MHO in adolescents.  We suggest that our primary definition may be reasonable criteria as it 
considers not only the number of metabolic conditions, but also the severity, to determine 
metabolic health status.  This means that our MHO adolescents do not have clinically 
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diagnosable comorbidities or clustering of pre-clinical risk factors: both of which are clear 
markers of ill health. 
The etiology of cardiometabolic health has been debated with some arguing that insulin 
resistance is the central feature, while others suggest that obesity is the primary factor29.  Obesity 
is one of the most consistent predictors of MHO in adolescents in the current study and past 
literature5,8.  Insulin resistance is not examined as frequently, but is also identified as an 
important predictor of MHO21,59.  Our study reports that both abdominal obesity and insulin 
resistance are predictors of MHO in obese adolescents, independent of lifestyle factors.  Insulin-
resistance, however was observed to be more closely associated with MHO than obesity, 
especially in females.  Obesity, insulin-sensitivity and metabolic health are highly inter-related 
and co-exist in adolescents with obesity.  Within our MHO youth (Definition 1), we observe that 
although 31% were insulin sensitive, only 7% had a normal WC, and only 4% had both insulin 
sensitivity and a normal WC (data not shown).  While it is debated whether insulin-resistance 
precedes obesity or obesity precedes insulin-resistance, both obesity and insulin-resistance have 
been proposed to be the responsible for cardiometabolic dysfunction29, and are influenced by 
lifestyle factors. 
 
In comparison to the literature on obesity and insulin-resistance, the associations between 
dietary components and cardiometabolic health in youth are weak and inconsistent.  For instance, 
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lower fiber36, polyunsaturated fat intake37 and protein38 and higher carbohydrate39, saturated 
fat40, and total fat39 have all been inconsistently associated with poorer cardiometabolic health in 
youth.  However, only one previous study has investigated the relationship between dietary 
components and MHO in youth and reported a negative association between dietary fat intake 
with MHO8.  The present study presents conflicting results, as only a higher polyunsaturated fat 
intake is independently related with MHO in females, whereas diet does not independently 
predict MHO in males.  These inconsistent findings may highlight the complexity of how diet 
relates to health, as there may be several dietary approaches by which to attain a lower body 
weight or improved insulin sensitivity that are not fully captured by our statistical analyses.  
Studies on physical activity have been more consistent in demonstrating positive effects 
on cardiometabolic health in youth43.  These effects are mainly related to improvements in 
adiposity and cardiorespiratory fitness, although independent effects are also observed43.  Indeed, 
physical activity is associated with acute improvements in several facets of health60  The 
relationship between physical activity and MHO in youth is less clear as only three studies have 
investigated this relationship.  One of these studies reported a positive association8 between 
physical activity and MHO, whereas the study, by Camhi et al.4 as well as the present study 
reported no association.  The absence of an association between physical activity and MHO in 
the present study may be explained by the high prevalence of adolescents participating in 
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physical activity in our sample (87%; data not shown) as most health benefits are obtained when 
transitioning from a state of inactivity to being active61.  Alternatively, factors such as 
musculoskeletal or cardiorespiratory fitness or sedentary behavior were not available but may 
provide added insight as to why some obese youth develop metabolic aberrations versus those 
who do not.      
This study has limitations to consider.  First, several factors that have been demonstrated 
to influence the MHO status of adolescents were not accounted for, such as visceral fat62, neck 
circumference9, uric acid concentration21, adiponectin63 and hepatic steatosis5.  Second, data on 
diet and physical activity is subject to self-reporting biases, for example under-reporting is 
especially pronounced in obese and adolescent populations64.  However, this should not affect the 
integrity of our results, unless MHO and MUO adolescents reported behaviours differently.  
Also, data on diet for the years 1999-2002 was based solely on one 24-hr diet recall and in the 
years 2003-2010, data was an average of only two 24-hr diet recalls.  This may have been 
insufficient to capture the regular dietary habits of these adolescents and may explain the 
unexpected relationships observed between dietary components with MHO in males.  Further, 
MUO adolescents may have been actively engaging in healthier behaviours to reduce obesity-
related comorbidities.  Finally, this study is cross-sectional in design, thus causality cannot be 
inferred from the associations observed.  
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In conclusion, this study demonstrated that 7 to 74% of youth with obesity are 
metabolically healthy, depending on the definition used.  The likelihood of being MHO 
significantly decreases with higher levels of obesity and insulin-resistance.  Conversely, diet, 
physical activity and inflammation were not as consistent in distinguishing MHO from MUO 
adolescents.  These findings highlight the need for effective strategies of managing obesity and 
insulin-resistance to achieve or maintain metabolic health in adolescents with obesity. 
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Chapter Seven: General Discussion 
Many changes in society may have contributed to today’s rise in obesity, including but 
not limited to the adoption of sedentary lifestyles and the abundance of readily available foods 
with a high caloric content65.  The obesity pandemic is not only apparent in developed countries 
but is also rapidly emerging in developing countries, even amongst children and adolescents65.  
In North America, the prevalence of obesity in adolescents has tripled in the past three decades 
and the prevalence of abdominal13 and severe obesity66 has increased at an even faster rate than 
general obesity.  This is alarming, as we have demonstrated that abdominal obesity is one of the 
most consistent predictors of cardiometabolic health in adolescents, even in our study with a 
narrow obese range.  Further, previous studies demonstrate that obesity tracks well into 
adulthood67, therefore the future metabolic health of the abdominally obese adolescents is 
unclear.  Insulin-resistance was also associated with MHO and is strongly associated with 
abdominal obesity24.  Thus, the prevention, management and treatment of obesity, particularly 
abdominal obesity, may be a solution to managing overall cardiometabolic health in adolescents.  
However, obesity management at the population level has proven to be extremely challenging, 
with not one country to date having succeeded in reducing its obesity rates68.  Fortunately, many 
policy makers have taken interest in addressing the issue of obesity and a multitude of research is 
currently published on the topic.  In Canada alone, the Canadian Obesity Network comprises 
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over 10,000 members including health care providers, policy makers, researchers and policy 
stake holders that are working together to prevent, manage, and treat obesity as well as obesity-
related health complications69. 
Still, the question of how to address the issue of obesity in adolescents remains 
unanswered.  As only 7-9% of adolescents with obesity are free of comorbidities, promoting 
obesity management and treatment amongst all adolescents with obesity, regardless of the 
presence of comorbidities, may be a simple yet functional method of improving cardiometabolic 
health in adolescents at a population level.  In fact, promoting weight loss even for adolescents 
with MHO may be beneficial for numerous reasons: i) obesity-related comorbidities may still 
develop with age70, ii) other psychological or health issues may be present despite the absence of 
cardiometabolic aberrations, iii) the incidence of mortality is increased in all individuals with 
obesity, regardless of metabolic health status17 and iv) beneficial effects on cardiometabolic 
health are observed with a only modest decrease in body weight percentage, even in individuals 
with MHO71.  However, prescribing weight loss and/or obesity management to all adolescents, 
including MHO adolescents may lead to frustration as a low rate of weight loss maintenance 
exists in the obese population72 and as a result, attempts to lose weight often lead to weight 
cycling which is associated with cardiometabolic dysfunction73.  Taking these factors into 
consideration, it is unclear whether weight loss or weight maintenance should be promoted in all 
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adolescents with obesity, including adolescents with MHO.  In adults, the EOSS recommends 
weight loss for MUO individuals and the prevention of further weight gain for MHO 
individuals18.  A scale has not yet been fully developed for pediatrics, however, preliminary 
work has been completed, suggesting that pediatric recommendations for weight management 
according to health status are likely forthcoming74. 
Although we have demonstrated that lower obesity and insulin-resistance are associated 
with a healthier cardiometabolic profile, physical activity was not associated with MHO and 
associations between diet and MHO were inconsistent across definitions of MHO.  Therefore, it 
is possible that methods by which a healthier cardiometabolic profile are maintained through diet 
and physical activity may vary from individual to individual.  For instance, diet and physical 
activity behaviours that influence the cardiometabolic health of one adolescent with obesity may 
not have the same influence on another adolescent with obesity.  Alternatively, there may be 
multiple combinations of diet and physical activity behaviours that are associated with lower 
obesity and a healthier cardiometabolic profile, therefore not one single dietary or physical 
activity component alone would consistently be related to MHO.  
 In conclusion, the present study has demonstrated that the prevalence of MHO varies 
considerably according to the criteria used to define MHO.  Therefore, future studies may benefit 
from harmonizing the definition of MHO.  We propose a definition of MHO that excludes 
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adolescents with clinically elevated comorbidities and clustering of pre-clinical cardiometabolic 
risk factors, both of which are markers of ill health.  The present study has also investigated the 
association of obesity, diet, physical activity and laboratory measures with MHO during 
adolescence, a time in life where health behaviours and cardiometabolic risk factors track into 
adulthood.  We have demonstrated that both lower obesity and lower insulin resistance are 
consistently associated with MHO.  Further research is required to investigate successful 
methods of attaining and maintaining lower obesity and insulin resistance at a population level.   
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Table 1: Clinical and metabolic syndrome thresholds of cardiometabolic risk factors. 
Risk Factor Pre-clinical Metabolic Syndrome Threshold Clinical Threshold 
Triglycerides ≥ 1.24 mmol/L75 ≥ 1.47 mmol/L34 
Glucose ≥ 5.55 mmol/L34 ≥ 7.0 mmol/L76 
HDL-C ≤ 1.04 mmol/L34 < 1.04 mmol/L34 
BP SBP or DBP ≥90th percentile for sex, age and height 
for 12-17 year old youth34 and ≥130/85 mmHg for 18 
and 19 year old youth75 
current use of hypertension medication  
or SBP or DBP ≥95th percentile for sex, age and  
height34 for 12-17 year old youth and SBP or  
DBP≥140/90 mmHg for 18 and 19 year old youth34 
CRP 
 
≥ 3 mg/L48 
HOMA-IR  ≥ 3.1677 
Abbreviations: HDL-C: High-Density Lipoprotein Cholesterol, BP: Blood Pressures, SBP: Systolic Blood Pressure, DBP: Diastolic 
Blood Pressure, CRP: C-Reactive Protein, HOMA-IR: Homeostatic Model Assessment of Insulin Resistance. 
35 
 
 
1A 
 
 
 
 
 
 
 
 
 
1B 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1A&B: Prevalence of cardiometabolic risk factors in male and female adolescents.   
 
Clinical thresholds: HOMA-IR≥3.16, CRP≥3.0 mg/L, triglycerides≥1.47mmol/L, glucose≥7.0mmol/L and BP (currently taking 
medication for hypertension or SBP or DBP ≥95th percentile for sex, age and height for youth under 18, and ≥140/90 mmHg for 18 
and 19 year old youth).  Metabolic syndrome thresholds: triglycerides≥1.24 mmol/L, glucose≥5.55 mmol/L, BP (SBP or DBP ≥90th 
percentile for sex, age and height for youth under 18, and ≥130/85 mmHg for 18 and 19 year old youth), HDL-C≤1.04 mmol/L. 
 
Abbreviations: M: Males, F: Females, HOMA-IR: Homeostatic model assessment of insulin resistance, CRP: C-Reactive Protein, BP: 
Blood Pressure, HDL-C: High-Density Lipoprotein Cholesterol. 
 
†Significant sex difference in the prevalence of clinically elevated risk factors (p<0.05).   
*Significant sex difference in the prevalence of metabolic syndrome risk factors (p<0.05). 
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Table 2: Descriptive characteristics of MHO and MUO adolescents by sex and metabolic health status. 
Data are presented as means±standard errors. 
Abbreviations: MHO: Metabolically Healthy Obesity, MUO: Metabolically Unhealthy Obesity, PIR: Poverty Income Ratio (socioeconomic status),  
WC: Waist Circumference, MPA: Moderate Physical Activity, VPA: Vigorous Physical Activity. 
-Variable not included in model. 
*PR significant at p<0.05. 
**PR significant at p<0.01. 
  Males (n=316) Females (n=316) 
 Primary Definition Secondary Definition Primary Definition Secondary Definition 
  MHO MUO MHO MUO MHO MUO MHO MUO 
 
(n=142) (n=174) (n=21) (n=295) (n=214) (n=102) (n=27) (n=289) 
Age (y) 14.9±0.2 15.5±0.2* 15.3±0.2 15.2±0.1 15.0±0.3 15.0±0.3 14.9±0.4 15.0±0.2 
PIR 2.3±0.2 2.6±0.1* 3.1±0.3 2.4±0.1** 2.4±0.1 2.3± 0.2 3.1±0.3 2.2±0.1** 
Obesity         
   BMI Percentile 97.6±0.1 98.3±0.1** 97.4±0.2 98.1±0.1** 97.4±0.1 97.1±0.2 97.1±0.2 97.6±0.1 
   WC (cm) 100.2±0.9 108.1±1.3** 96.2±1.1 105.4±0.7* 100.7±0.8 104.5±1.6 95.7±0.6 102.5±0.8** 
Diet         
   Energy (kcal) 2334±83 2138±93 2210±105 2221±66 1674±58 1738±78 1693±213 1690±42 
   Total fat (g) 87.8±4.1 77.4±3.8* 82.4±4.5 81.7±3.1 63.2±2.8 64.3±3.8 65.7±11.4 63.2±2.1 
   Saturated fat (g) 29.9±1.3 26.5±1.3* 29.8±1.4 27.8±1.0 21.5±1.2 23.1±1.4 20.8±4.4 22.1±0.8 
   Monounsaturated fat (g) 32.9±1.6 28.7±1.4* 30.0±1.9 30.5±1.1 23.5±1.1 24.2±1.5 26.0±4.0 23.4±0.8 
   Polyunsaturated fat (g) 17.4±1.1 16.0±1.1 15.3±0.9 16.7±0.9 13.1±0.6 11.8±0.9 14.1±2.5 12.6±0.5 
   Carbohydrates (g) 298.7±10.3 286.4±13.0 285.9±14.8 292.0±8.6 223.0±6.9 232.9±12.6 229.8±23.1 225.1±5.4 
   Protein (g) 90.1±3.0 79.0±3.6** 85.6±4.3 83.5±2.7 57.6±2.3 60.4±2.9 51.3±7.7 59.3±1.6 
   Fiber (g) 14.1±0.6 12.6±0.5* 11.6±1.0 13.3±0.4* 10.4±0.4 10.6±0.8 10.2±1.9 10.5±0.3 
   Cholesterol (mg) 299±18 258±15* 283±32 275±14 188±13 204±17 157±39 197±11 
Physical Activity        
   MPA  (min/week) 192±20 189±41 270±86 184±27** 135±16 124±29 164±73 128±14 
   VPA  (min/week) 314±34 244±25 324±55 269±21* 171±24 140±27 55±34 177±19** 
Health Measures         
   Insulin-resistance 4.5±0.2   6.8±0.7** - - 4.4±0.2   6.6±0.5** - - 
   Inflammation (mg/L) 0.3±0.0 0.2±0.0 - - 0.4±0.0    0.4±0.1 - - 
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Table 3. Associations between obesity, diet, physical activity and laboratory measures with risk of prevalent MHO. 
PR are presented per unit SE and are adjusted for age and PIR (socioeconomic status). 
Abbreviations: MHO: Metabolically Healthy Obesity, PR: Prevalent Risk, CI: Confidence Intervals, SE: Standard Error, WC: Waist Circumference, 
MPA: Moderate Physical Activity, VPA: Vigorous Physical Activity, MVPA: Moderate-Vigorous Physical Activity. 
-Variable not included in model. 
aFurther adjusted for energy intake. 
bFurther adjusted for energy intake and fiber. 
*PR significant at p<0.05. 
**PR significant at p<0.01.
  Males  Females 
  Primary Definition Secondary Definition  Primary Definition Secondary Definition 
  SE PR of MHO (95% CI) PR of MHO (95% CI) SE PR of MHO (95% CI) PR of MHO (95% CI) 
Obesity       
   BMI Percentile 0.1 0.97 (0.96-0.99)** 0.96 (0.94-0.98)** 0.1 0.98 (0.95-1.01) 0.98 (0.95-1.01) 
   WC (cm) 0.7 0.92 (0.88-0.96)** 0.92 (0.88-0.96)** 0.7 0.98 (0.96-1.00) 0.95 (0.93-0.98)** 
Diet       
   Energy (kcal) 63 1.02 (1.00-1.04) 1.00 (0.98-1.01) 46 0.99 (0.98-1.01) 1.00 (0.96-1.03) 
   Total fat (g)a 2.9 1.02 (0.99-1.05) 1.01 (0.97-1.10) 2.3 1.02 (0.97-1.07) 1.03 (0.97-1.09) 
   Saturated fat (g)a 1.0 1.02 (0.99-1.04) 1.04 (1.01-1.08)** 0.9 0.98 (0.93-1.03) 0.97 (0.90-1.04) 
   Monounsaturated fat (g)a 1.1 1.02 (0.99-1.06) 1.00 (0.96-1.04) 0.9 1.00 (0.96-1.05) 1.05 (1.01-1.10)* 
   Polyunsaturated fat (g)a 0.8 1.00 (0.97-1.02) 0.99 (0.97-1.00) 0.5 1.05 (1.01-1.08)** 1.04 (1.00-1.08) 
   Carbohydrates (g)b 8.2 0.96 (0.92-1.00)* 0.99 (0.95-1.02) 5.5 1.00 (0.95-1.04) 1.01 (0.96-1.07) 
   Protein (g)a 2.5 1.03 (1.00-1.05)* 1.01 (0.97-1.05) 1.8 0.99 (0.96-1.03) 0.94 (0.86-1.02) 
   Fiber (g)a 0.4 1.00 (0.99-1.04) 0.98 (0.95-1.01) 0.4 1.00 (0.97-1.03) 0.99 (0.95-1.03) 
   Cholesterol (mg)a 13.0 1.01 (1.00-1.03)* 1.01 (0.98-1.04) 11.0 0.99 (0.97-1.02) 0.97 (0.91-1.03) 
Physical Activity       
   MPA  (min/week) 27 1.00 (0.99-1.02) 1.01 (0.98-1.04) 14 1.00 (0.98-1.03) 1.01 (0.97-1.06) 
   VPA (min/week) 19 1.01 (1.00-1.02) 1.01 (0.99-1.02) 18 1.01 (0.99-1.03) 0.93 (0.83-1.04) 
   MVPA  (min/week) 35 1.01 (1.00-1.02) 1.01 (0.99-1.03) 22 1.01 (0.99-1.02) 0.98 (0.94-1.03) 
Laboratory Measures       
   Insulin-resistance 0.4 0.91 (0.88-0.95)**             - 0.2 0.95 (0.92-0.97)**             - 
   Inflammation (mg/L) 0.0 1.00 (0.99-1.02)             - 0.0 0.99 (0.97-1.01)             - 
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Table 4. Independent associations between obesity, diet, physical activity and laboratory measures with risk of prevalent MHO. 
Each column includes the most the most significant obesity, diet, physical activity and laboratory factors for that definition from Table 3. 
PR are presented per unit SE and are mutually adjusted for the other obesity, diet, physical activity and laboratory variables in the model and are further 
adjusted for age and PIR (socioeconomic status). 
- Variable not included in model. 
aFurther adjusted for energy intake. 
bFurther adjusted for energy intake and fiber. 
 
Abbreviations: MHO: Metabolically Healthy Obesity, PR: Prevalent Risk, CI: Confidence Intervals, SE: Standard Error, WC: Waist Circumference, 
VPA: Vigorous Physical Activity, MVPA: Moderate-Vigorous Physical Activity. 
 
*PR significant at p<0.05. 
**PR significant at p<0.01. 
 
 
 
 
 
 
  Males  Females 
  Primary Definition Secondary Definition  Primary Definition Secondary Definition 
SE PR of MHO (95% CI) PR of MHO (95% CI) SE PR of MHO (95% CI) PR of MHO (95% CI) 
Obesity 
      
   WC (cm) 0.7 0.97 (0.95-0.99)** 0.92 (0.88-0.96)** 0.7 0.99 (0.97-1.01) 0.95 (0.93-0.97)** 
Diet 
      
   Saturated fat (g)a 1.0 - 1.01 (0.98-1.03) - - - 
   Monounsaturated fat (g)a - - - 0.9 - 1.01 (0.97-1.05) 
   Polyunsaturated fat (g)a - - - 0.5 1.02 (1.00-1.04)* - 
   Carbohydrates (g)b 8.2 
 
8.2 1.01 (0.99-1.03) - - - - 
Physical Activity 
      
   VPA (min/week) 19 1.00 (0.99-1.02) - 18 - 0.92 (0.82-1.03) 
   MVPA  (min/week) 35 - 1.01 (0.99-1.02) 22 1.01 (0.99-1.02) - 
Laboratory measures       
   Insulin-resistance 0.4 0.94 (0.91-0.97)** - 0.2   0.95 (0.92-0.98)**  
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